Key result
ACTH-stimulated aldosterone may guide personalized primary aldosteronism management and MRA treatment by assessing vascular health.
Why the study?
Differences in aldosterone responsiveness to ACTH between APA and IHA subtypes of primary aldosteronism and their impacts on vascular function and treatment outcomes were unclear.
Does aldosterone responsiveness to ACTH stimulation differ between APA and IHA subtypes of primary aldosteronism and predict vascular function or treatment outcomes?
Observational (n=97)
Does aldosterone responsiveness to ACTH stimulation differ between APA and IHA subtypes of primary aldosteronism and predict vascular function or treatment outcomes?
ACTH-stimulated aldosterone responsiveness may serve as a useful biomarker to assess vascular health and predict blood pressure normalization following MRA therapy in patients with primary aldosteronism.
Answers are grounded in this paper and cite their sources.
Supports vascular assessment-guided MRA therapy in primary aldosteronism; extends personalized management but requires prospective validation.
Objective This study examined differences in aldosterone responsiveness to adrenocorticotropic hormone (ACTH) between the unilateral aldosterone-producing adenoma (APA) and bilateral idiopathic hyperaldosteronism (IHA) subtypes of primary aldosteronism (PA) and the impacts on vascular function and treatment outcomes.Methods This retrospective study enrolled 97 patients with PA (63 with APA and 34 with IHA) who underwent adrenal venous sampling (AVS) with ACTH stimulation. During AVS, baseline and ACTH-stimulated plasma aldosterone concentration (PAC) and cortisol levels were also assessed. Vascular function was assessed by measuring flow-mediated dilation (FMD). APA tissues were analyzed for KCNJ5 mutations.Results Among 97 patients with PA, those with APA showed higher baseline and ACTH-stimulated plasma aldosterone concentration levels, which correlated inversely with FMD. In patients with IHA, the logarithmic difference between PAC measurements before and after ACTH stimulation correlated positively with the blood pressure-normalization effect after mineralocorticoid receptor antagonist (MRA) therapy, with a cutoff value of 2.140 for predicting treatment response.Conclusion These findings suggest that ACTH-stimulated aldosterone may offer a useful marker for personalized management of PA, particularly in assessing vascular health and guiding MRA treatment.
No takes yet. Share an insight, caveat, or question.
Watanabe et al. (2026) conducted an observational in Primary aldosteronism (n=97). Aldosterone responsiveness to adrenocorticotropic hormone stimulation vs. Unilateral aldosterone-producing adenoma vs bilateral idiopathic hyperaldosteronism was evaluated on Vascular function (flow-mediated dilation) and blood pressure-normalization after mineralocorticoid receptor antagonist therapy. Aldosterone responsiveness to ACTH stimulation correlated inversely with flow-mediated dilation in APA and predicted blood pressure normalization after MRA therapy in IHA (cutoff value 2.140).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: